Asensus Surgical

Asensus Surgical, Inc. is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System features a machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit (ISU) that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world while staying true to the principles of value-based healthcare. The company was founded by William N. Starling on August 19, 1988 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Asensus Surgical reports Q1 loss but eyes stability through acquisition

Asensus Surgical's Q1 2024 performance showed a significant net loss, but the potential acquisition by KARL STORZ offers financial stability. The company aims to sustain operations into Q3 2024 and beyond with available cash and additional financing. Ongoing initiatives focus on advancing surgical systems and expanding global programs.

Asensus Surgical reports Q2 losses, merger vote adjourned

Asensus Surgical faces financial struggles with a significant net loss and liquidity concerns.
The proposed merger with Karl Storz offers a potential strategic advantage but hinges on stockholder approval.
Addressing operational inefficiencies and investor engagement are critical for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical is a digital interface between the surgeon and patient to improve minimally invasive surgery through digital laparoscopy. They enable capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seek to address the current clinical, cognitive, and economic shortcomings in surgery.

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 20.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q2 Loss, Misses Revenue Estimates

RESEARCH TRIANGLE PARK, N.C., July 26, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical , Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 second quarter financial and operating results after the market closes on Monday, August 8, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 8, 2022

This becomes the 6th Senhance Hospital in Germany This becomes the 6th Senhance Hospital in Germany

Asensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital Tübingen

RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company will be participating in the Society of Robotic and Digital Surgery Conference from June 30, 2022 until July 3, 2022 in Lake Buena Vista, Florida.

Asensus Surgical to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical Inc. (NYSE:ASXC ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mark Klausner - Westwicke Partners, Investor Relations Anthony Fernando - President & Chief Executive Officer Shameze Rampertab - Executive Vice President & Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co. Operator Greetings and welcome to Asensus Surgical Inc. 2022 First Quarter Financial and Operating Results Conference Call.

Asensus Surgical Inc. (ASXC) CEO Anthony Fernando on Q1 2022 Results - Earnings Call Transcript

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q1 Loss, Lags Revenue Estimates

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the first quarter 2022. Recent Highlights Over 650 procedures were performed globally during the quarter, representing growth of 31% over the prior year quarter First quarter revenue of $1.1 million The

Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2022

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2022 first quarter financial and operating results after the market closes on Wednesday, May 4, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 4, 2022

Asensus Surgical is leading the digital surgical market with Performance-Guided Surgery(TM)New York, New York--(Newsfile Corp. - April 20, 2022) - PCG Digital -- Surgery can be unpredictable, and a staggering one in five patients undergoing surgery has one, or even multiple, preventable surgical complications.Asensus Surgical (NYSE American: ASXC) is setting a new standard for robotic, laparoscopic surgery with its technology platform, Senhance®, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence (AI) and machine learning (ML). The Senhance system provides surgeons with real-time...

Investing in 60 Seconds: Asensus Surgical

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 7.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q4 Loss, Tops Revenue Estimates

Asensus Surgical Inc. (ASXC) CEO Anthony Fernando on Q4 2021 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the fourth quarter and full year 2021. Fourth Quarter Highlights Over 500 procedures were performed globally during the quarter, representing growth of 30% over the fourth quarter 2020 Six Senhance Surgi

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2021 fourth quarter and fiscal year 2021 financial and operating results after the market closes on Monday, February 28, 2022. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the s

Asensus Surgical, Inc. Schedules Fourth Quarter and Fiscal Year 2021 Financial and Operating Results Conference Call for February 28, 2022

Setting a new standard with Performance-Guided SurgeryNew York, New York--(Newsfile Corp. - January 26, 2022) - -- PCG Digital-- Asensus Surgical, Inc. (NYSE American: ASXC) is leading the digital surgical market with a new concept known as Performance-Guided Surgery™. Asensus SurgicalTo view an enhanced version of this graphic, please visit:

Asensus Surgical: Reimagining the Future of Surgery

Asensus Surgical's Senhance Surgical System is being more widely adopted by surgeons.

Is This Rapidly Growing Surgical Robotics Stock a Buy?

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2021 year-end corporate update. Fourth Quarter Highlights Over 500 procedures were performed globally during the quarter, representing growth of over 25% over the fourth quarter 2020 Six Senhance Surgical Programs were initiated d

Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

Ambev

AcelRx Pharmaceuticals

Are these penny stocks on your January 2022 watchlist? The post Best Penny Stocks to Buy In January 2022?

Best Penny Stocks to Buy In January 2022? 3 Investors Are Watching

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the 40th Annual J.P. Morgan Healthcare Conference. The Company's virtual presentation will take place on Thursday, January 13, 2022 at 9:00 am Eastern Time. In addition, the Company will participate in the H.C. Wainwright Bioconnect

Asensus Surgical to Participate in the 40th Annual J.P. Morgan Healthcare Conference and H.C.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don (“RZD Medicine”), located in Rostov, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System. “We a

Asensus Surgical Announces Purchase of Senhance Robotic System by RZD Medicine

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the Franklin Medical Center in Winnsboro, Louisiana has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are excited to bring the Senhance system's unique capabilities to yet another innovative hospital in the Un

Asensus Surgical Announces Franklin Medical Center to Initiate the Installation of the Senhance Surgical System

Surgical Robots market will grow at a rapid pace (CAGR of 20.1%) in the future. ASXC's Senhance System and other products are achieving regulatory clearances from U.S., Europe, and Asian authorities.

Asensus Surgical: Surgical Robot Company

Alzamend Neuro

Progenity

Which biotech penny stocks are you watching this month? The post Best Biotech Penny Stocks to Buy in November?

Best Biotech Penny Stocks to Buy in November? 3 to Watch Now

Earnings results for the third quarter look great, until you peek under the hood.

Why Asensus Surgical Stock Is Moving Up Today

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0.00% and 152.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Asensus Surgical (ASXC) Reports Q3 Loss, Tops Revenue Estimates

Asensus Surgical, Inc. (ASXC) CEO Anthony Fernando on Q3 2021 Results - Earnings Call Transcript

News for Asensus Surgical Stock (ASXC)